Cumulative incidence RATE of CNS progression
(IRC, ITT)
(
ALEX Study
)
Alectinib delayed CNS progression in patients with and
without CNS metastases at baseline compared with crizotinib
Gadgeel SM et al. ESMO 2017 (Abstract 12980)